Watchlist Price Alert

ARS Pharmaceuticals Inc. (SPRY)

NASDAQ: SPRY · Real-Time Price · USD

14.99

0.47 (3.24%)

At close: May 23, 2025, 3:59 PM

15.12

0.87%

After-hours: May 23, 2025, 04:57 PM EDT

3.24% (1D)

Bid	14
Market Cap	1.47B
Revenue (ttm)	97.12M
Net Income (ttm)	-15.65M
EPS (ttm)	-0.16
PE Ratio (ttm)	-93.69
Forward PE	-20.47
Analyst	Buy

Ask	15.15
Volume	2,115,536
Avg. Volume (20D)	1,727,000
Open	14.50
Previous Close	14.52
Day's Range	14.49 - 15.29
52-Week Range	7.55 - 18.51
Beta	0.94

About SPRY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SPRY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SPRY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

ARS Pharmaceuticals has released their quartely earnings on May 14, 2025:

Revenue of $7.97M exceeds estimates by $493K, with Infinity% YoY growth.

EPS of -0.35 exceeds estimates by 0.01, with -218.18% YoY decline.

Why Price Moved

1 week ago

+11.48%

ARS Pharmaceuticals shares are trading higher on p... Unlock content with Pro Subscription

2 months ago

+22.83%

ARS Pharmaceuticals shares are trading higher. The company reported Q4 financial results.

News

1 week ago · seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas ...

1 week ago · zacks.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.

3 weeks ago · seekingalpha.com

ARS Pharmaceuticals Has A Blockbuster Candidate

ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and i...

2 months ago · seekingalpha.com

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's co...

2 months ago · seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, Presiden...

2 months ago · investors.com

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.

Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.

2 months ago · zacks.com

ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year...